Beyond The Printed Page

  1. Can Boston And San Francisco Remain The Center Of Biopharma’s Universe?
    12/13/2017

    Three top biopharmaceutical executives share their ideas on what bio clusters biopharmaceutical executives should be paying attention to for 2018. In addition, insights are provided on other future potential bio hot spots.

  2. Want To Know What 5 Biopharmaceutical CEOs Anticipate For 2018 & Beyond?
    12/5/2017

    Five top biopharmaceutical executives share their thoughts on Big Data, industry trends, personalized medicine, and more in preparing you for what to expect in 2018 – and beyond.

  3. Diverse Perspectives — Insights for 2018 From Biopharma’s Leading Women
    11/30/2017

    Five female biopharmaceutical industry CEOs share exclusive insights on what to expect for 2018 and beyond.

  4. Five Questions With Lilly’s Daniel Skovronsky, M.D., Ph.D.
    11/13/2017

    Daniel Skovronsky, M.D., Ph.D., former CEO of Avid Radiopharmaceuticals, sold his company to Eli Lilly and Company in 2010 for $300 million -- $850 million if you add in all the milestones achieved. This successful biopharmaceutical entrepreneur shares personal insights on the process of valuing his company prior to acquisition, his philosophy on optionality, and what if anything he’d do differently.

  5. A Woman Leader On The Subject Of Women As Leaders
    11/6/2017

    Can women leaders be responsible and liked – at the same time? Sophie Kornowski-Bonnet, head of Roche partnering, discusses her approach to overcoming adversity, leading to an interesting discussion on if there are differences beyond gender for male versus female executives.

  6. The Intriguing Career Path Of Roche’s Head Of Partnering
    10/25/2017

    What’s it take to get to the c-suite of a biopharmaceuticals company? For Sophie Kornowski-Bonnet, it was a willingness to step out of her comfort zone. The current head of Roche partnering and executive committee member, shares her intriguing career path, which began in Paris, France, back in 1986.

  7. Daniel Skovronsky – From Grad Student, To CEO, To Big Pharma
    10/16/2017

    Prior to joining Lilly as SVP of clinical and product development, Daniel Skovronsky, M.D., Ph.D. was CEO of Avid Radiopharmaceuticals — a company he founded while still a graduate student. This article is a prequel to the upcoming feature in our November issue that explores how he built a $300 million company.

  8. Does The Biopharmaceutical Industry Need To Broaden Its Horizons?
    10/10/2017

    When I interviewed Axovant Sciences CEO David Hung, one of the questions posed was sparked by our discussion of his experience at Pro-Duct Health and his invention of a microcatheter for early detection of ductal breast cancer in women. As he explained his medical device invention, Hung commented, “I don’t want to be just medicines, or just devices, or anything like that.”

  9. What Might Be The Best Predictor Of Future Performance At Axovant Sciences?
    9/12/2017

    Chief Editor Rob Wright recently conducted an in-person interview with David Hung, formerly of Medivation and current  CEO of Axovant Sciences. Though many may credit the FDA’s approval of Medivation’s Xtandi (enzalutamide) as being the primary driver behind Hung’s rise, Wright argues that there are a number of other predictors that should be evaluated when anticipating future success.

  10. Allergan’s Brent Saunders Shares A Social Contract Secret
    9/1/2017

    Don't miss this free (all-access) sneak peek of our upcoming September feature article on how Brent Saunders built Allergan’s social contract, a document that may likely define his biopharma legacy. “Over time, as people evaluate my leadership in the role, I hope it is not limited to the social contract," he says.